

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 21, 2024

Reference is made to the circular (the “**Circular**”) of Innovent Biologics, Inc. (the “**Company**”) incorporating, amongst others, the notice (the “**Notice**”) of annual general meeting of the Company (the “**AGM**”) dated May 29, 2024. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

All the Directors, namely Dr. De-Chao Michael Yu as Chairman and executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen, Mr. Gary Zieziula, Dr. Shun Lu and Mr. Shuyun Chen as independent non-executive Directors attended the AGM in person or by electronic means.

At the AGM held on June 21, 2024, all the proposed resolutions as set out in the Notice were duly passed by way of poll and the poll results were as follows:

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
1.	To consider and receive the audited consolidated financial statements of the Company and the reports of the directors (the “ Directors ”) and the auditor of the Company for the year ended December 31, 2023	1,033,309,098 (99.967136%)	339,700 (0.032864%)
2(i).	To re-elect Ms. Qian Zhang as an executive Director	1,027,991,804 (99.484910%)	5,322,500 (0.515090%)
2(ii).	To re-elect Dr. Shun Lu as an independent non-executive Director	1,031,263,798 (99.782296%)	2,250,000 (0.217704%)
2(iii).	To re-elect Dr. Kaixian Chen as an independent non-executive Director	1,007,893,179 (97.521273%)	25,617,922 (2.478727%)
2(iv).	To re-elect Ms. Joyce I-Yin Hsu as an independent non-executive Director	974,078,055 (94.237277%)	59,566,041 (5.762723%)
2(v).	To re-elect Mr. Shuyun Chen as an independent non-executive Director	992,966,250 (96.076729%)	40,547,548 (3.923271%)
3.	To authorise the board of Directors (the “ Board ”) to fix the remuneration of the Directors	1,006,993,817 (97.439419%)	26,462,481 (2.560581%)

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
4.	To re-appoint Messrs. Deloitte Touche Tohmatsu as the external auditor of the Company and to authorize the Board to fix their remuneration	1,027,682,673 (99.422809%)	5,966,125 (0.577191%)
5.	To grant a general mandate to the Directors to buy back shares of the Company (excluding any shares that are held as treasury shares, if any)	1,032,831,798 (99.934012%)	682,000 (0.065988%)
6.	To grant a general mandate to the Directors to allot, issue and deal with additional shares of the Company (excluding any shares that are held as treasury shares, if any)	696,338,336 (67.375814%)	337,175,462 (32.624186%)
7.	To extend the general mandate granted to the Directors to issue shares of the Company by adding thereto the total number of the shares to be bought back by the Company (excluding any shares that are held as treasury shares, if any)	536,314,395 (51.892330%)	497,199,403 (48.107670%)
SPECIAL RESOLUTION		Number of Votes (%)	
		For	Against
8.	To approve and adopt the fifteenth amended and restated memorandum and articles of association of the Company in substitution for and to the exclusion of the existing fourteenth amended and restated memorandum and articles of association of the Company with immediate effect after the closing of the Annual General Meeting, and to authorise any one of the Directors to do all things necessary or expedient to implement the adoption of the fifteenth amended and restated memorandum and articles of association of the Company	1,033,505,798 (99.999226%)	8,000 (0.000774%)

As more than 50% of votes were cast in favor of the ordinary resolutions nos. 1 to 7 above, all such resolutions were duly passed by the shareholders as ordinary resolutions. As more than 75% of the votes were cast in favor of the special resolution no. 8, the resolution was duly passed by the shareholders as special resolution.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China
June 21, 2024

Notes:

- (a) As at the date of the AGM, the total number of shares of the Company in issue was 1,628,383,570 shares.
- (b) The total number of shares of the Company entitling the holders to attend and vote on the resolutions at the AGM was 1,628,383,570 shares.
- (c) There were no shares entitling the holder to attend and abstain from voting in favour of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules.
- (d) No shareholders of the Company were required under the Listing Rules to abstain from voting on the resolutions proposed at the AGM.
- (e) No parties have stated their intention in the Company's Circular to vote against or to abstain from voting on any of the resolutions proposed at the AGM.
- (f) The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.
- (g) The full text of the above resolutions are set out in the AGM Notice.

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as Executive Directors and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen, Mr. Gary Zieziula, Dr. Shun Lu and Mr. Shuyun Chen as Independent Non-executive Directors.